Dedifferentiated liposarcoma – Diagnostics

Go back

Diagnosing dedifferentiated liposarcoma requires a careful combination of physical examination, imaging studies, and tissue analysis. Since this rare cancer often grows slowly and without pain in its early stages, many people don’t realize they have it until a noticeable lump appears or symptoms develop from the tumor pressing on nearby structures.

Introduction: Who Should Undergo Diagnostics

Dedifferentiated liposarcoma is typically discovered when a person notices a growing lump or swelling on their body, particularly on the arms, legs, or torso. Because this condition is rare and often develops without early warning signs, knowing when to seek medical attention is important for early detection and treatment.[1]

You should consider seeking diagnostic evaluation if you notice a lump that continues to grow persistently over time, especially if it appears on your arm, leg, or torso. Unlike common fatty lumps called lipomas, which are harmless and usually stay small, dedifferentiated liposarcoma tends to grow larger and feel firmer to the touch. Most people with this condition are adults over the age of 50, with the median age at diagnosis being 68 years old, and it affects men slightly more often than women.[1]

When dedifferentiated liposarcoma develops in the arms or legs, it can cause noticeable symptoms such as swelling or numbness in the area around the lump, or weakness in the affected limb. If the tumor forms in the torso, particularly in the back of the abdominal cavity (an area called the retroperitoneum, which is the space behind the organs in your belly), it may cause stomach pain or cramping, or you might notice your abdomen gradually increasing in size.[1]

Sometimes, dedifferentiated liposarcoma is found accidentally during an investigation of other symptoms or during a routine operation for a different condition. When located in the abdominal cavity, the tumor may grow quite large before causing any symptoms, which is why it’s often discovered incidentally during imaging tests performed for other reasons.[4]

If you experience any of these symptoms, it’s advisable to start with a visit to your general practitioner. Your GP will examine you and, if necessary, refer you to a specialist doctor who can perform more detailed diagnostic tests. Early diagnosis is critically important because dedifferentiated liposarcoma has a greater chance of coming back after treatment and spreading to other parts of the body compared to other types of liposarcoma.[1]

⚠️ Important
Not all lumps are cancerous. Lipomas, which are benign noncancerous fatty tumors, are much more common than liposarcoma. If you find a fatty lump, your doctor will evaluate it by comparing characteristics such as consistency, location, size, and sensation. Lipomas feel soft and rubbery, while liposarcomas are usually firmer and can grow much larger, especially in deep tissue areas.

Diagnostic Methods

When dedifferentiated liposarcoma is suspected, doctors use a series of diagnostic tests to identify the disease and distinguish it from other conditions. These tests help determine the exact nature of the tumor, its size, location, and whether it has spread to other areas of the body.[1]

Physical Examination

The diagnostic process typically begins with a thorough physical examination. Your doctor will look at and feel any lump or swelling you’ve noticed. During this examination, the doctor checks for noticeable masses by examining and feeling the affected area. They will assess the size, location, and consistency of the lump, and may ask questions about when you first noticed it and whether it has been growing.[1][4]

The physical examination is an important first step because it helps the doctor decide which additional tests are needed. For example, a lump in your arm or leg can be examined more easily than one deep inside your abdomen, which might require more sophisticated imaging techniques to visualize properly.

Imaging Tests

After the physical examination, your doctor will typically order imaging tests to take detailed pictures of the inside of your body. These scans help assess the tumor’s size, location, and extent, and can also determine if the tumor has spread to nearby tissues or other parts of the body.[4]

CT scans (computed tomography scans) and MRI scans (magnetic resonance imaging) are the most commonly used imaging tests for diagnosing dedifferentiated liposarcoma. These scans create detailed cross-sectional images of your body, allowing doctors to see the tumor’s exact location and measure its size. They can also show whether the tumor is pressing on nearby structures like nerves, blood vessels, or organs, which helps explain any symptoms you might be experiencing.[4]

For tumors in the arms or legs, MRI scans are particularly useful because they provide excellent detail of soft tissues, including muscles, fat, and connective tissue. For tumors in the abdomen or retroperitoneum, CT scans are often preferred because they can show a larger area and are better at visualizing the relationship between the tumor and nearby organs.[4]

These imaging tests are not only important for diagnosis but also for planning treatment. Surgeons use the images to understand exactly where the tumor is located and how to approach removing it safely while preserving as much healthy tissue as possible.

Biopsy

A biopsy is the most definitive diagnostic test for dedifferentiated liposarcoma. This procedure involves taking a small sample of tissue from the tumor and examining it under a microscope. The biopsy allows doctors to identify the tumor’s characteristics and confirm whether it is indeed dedifferentiated liposarcoma rather than another type of tumor.[1]

The biopsy is often performed using an image-guided needle biopsy, where a doctor uses a CT scan or ultrasound to guide a needle into the tumor and extract a small tissue sample. This is less invasive than surgical biopsy and can usually be done as an outpatient procedure with local anesthesia.[4]

When examined under a microscope, dedifferentiated liposarcoma shows a distinctive pattern. The tumor is composed of two types of tissue: one part that resembles well-differentiated liposarcoma (which contains abnormal fat cells) and another part that is a high-grade non-fatty sarcoma. This combination is what defines dedifferentiation, meaning the tumor has progressed from a lower-grade to a higher-grade, more aggressive form.[2][4]

Laboratory analysis of the biopsy sample also looks for specific genetic abnormalities that are characteristic of dedifferentiated liposarcoma. The most important of these is the amplification (increased number of copies) of genes called MDM2 and CDK4, which are located on chromosome region 12q13-15. Detection of MDM2 amplification serves to distinguish dedifferentiated liposarcoma from other types of undifferentiated sarcomas, making it a crucial diagnostic marker.[2][7]

The biopsy results not only confirm the diagnosis but also provide information about the tumor’s grade, which indicates how abnormal the cancer cells look and how quickly they are likely to grow and spread. This information helps doctors predict the tumor’s behavior and plan the most appropriate treatment strategy.

Diagnostics for Clinical Trial Qualification

When patients with dedifferentiated liposarcoma are being considered for enrollment in clinical trials, additional diagnostic tests may be required beyond those used for standard diagnosis. These tests help researchers ensure that patients meet specific criteria for participation and allow them to monitor how well experimental treatments are working.[1]

Clinical trials investigating new treatments for dedifferentiated liposarcoma often require confirmation of the MDM2 gene amplification through specialized laboratory testing. This genetic marker is so characteristic of dedifferentiated liposarcoma that it has become a standard criterion for enrolling patients in trials testing drugs that target this specific abnormality.[2][7]

Some clinical trials may also require testing for additional genetic features beyond MDM2 and CDK4 amplification. Researchers have recently identified specific gene fusions (when two or more genes join together to form a new gene) called CTDSP1/2-DNM3OS in a subset of dedifferentiated liposarcoma cases. Patients with these particular genetic changes might be candidates for trials testing treatments designed to target these abnormalities.[2]

Staging scans are typically required for clinical trial enrollment to determine the extent of the disease. These may include chest CT scans to check for spread to the lungs, and abdominal or pelvic scans to evaluate the primary tumor and look for evidence of spread to other areas. The staging information helps researchers group patients with similar disease characteristics and ensures that trial results are meaningful and interpretable.[1]

Blood tests are another common requirement for clinical trial qualification. These tests assess your overall health and organ function to make sure you are healthy enough to receive experimental treatments. They typically include complete blood counts to check your red blood cells, white blood cells, and platelets, as well as tests of kidney and liver function. Some trials may also require specific biomarker testing in blood samples to monitor treatment response.[9]

Before starting a clinical trial, patients usually undergo baseline imaging studies that will be repeated at regular intervals during the trial to assess how the tumor responds to treatment. These images are carefully measured using standardized criteria called RECIST (Response Evaluation Criteria in Solid Tumors), which define how much a tumor must shrink to be considered responsive to treatment. However, researchers have noted that RECIST may not adequately capture all positive treatment effects in dedifferentiated liposarcoma, particularly vascular changes within these large heterogeneous tumors.[9]

If you are interested in participating in a clinical trial, your doctor will discuss which additional diagnostic tests are needed and explain how they will be used to monitor your condition throughout the trial. An ongoing clinical trial is currently investigating how suitable chemotherapy is as a treatment for dedifferentiated liposarcoma, and participants in this trial would need to meet specific diagnostic criteria for enrollment.[1]

Follow-up Diagnostics After Treatment

After completing treatment for dedifferentiated liposarcoma, you will have regular follow-up appointments for several years. These appointments include diagnostic tests to monitor for any signs of the sarcoma returning, since dedifferentiated liposarcoma has a relatively high rate of local recurrence.[1]

Your follow-up schedule should be provided by your sarcoma clinical nurse specialist. The usual practice includes a chance to discuss any new symptoms you may be experiencing, followed by a physical examination to look for any signs of recurrence. This examination may include an MRI or ultrasound if required, depending on where your original tumor was located and your individual risk factors.[1]

Regular imaging surveillance is particularly important for dedifferentiated liposarcoma because recurrence occurs in 40 to 75 percent of cases, and metastasis (spread to other parts of the body) occurs in about 10 to 15 percent of cases. Early detection of recurrence or metastasis through these follow-up diagnostics can allow for prompt treatment, which may improve outcomes.[1]

Prognosis and Survival Rate

Prognosis

The prognosis for dedifferentiated liposarcoma varies depending on several factors, including the tumor’s location, size, whether it can be completely removed surgically, and whether it has spread to other parts of the body. Unlike well-differentiated liposarcoma, which grows slowly and is less life-threatening, dedifferentiated liposarcoma is a high-grade aggressive tumor with a higher likelihood of local recurrence and metastasis.[4]

The tumor’s location plays a significant role in determining outcomes. Studies suggest that dedifferentiated liposarcoma cases occurring in the arms or legs tend to have better outcomes than those developing in the retroperitoneum (the back of the abdominal cavity). This is partly because tumors in the limbs can often be removed more completely with adequate margins of healthy tissue around them.[4]

Recurrence is a major concern with dedifferentiated liposarcoma. Local recurrence (the cancer coming back in the same area where it was originally found) occurs in 40 to 75 percent of cases. Metastasis, where the cancer spreads to distant parts of the body, occurs in about 10 to 15 percent of cases. These relatively high rates of recurrence and metastasis make long-term follow-up care essential.[1][4]

Survival Rate

The reported disease-related mortality rate for dedifferentiated liposarcoma is approximately 30 percent, meaning that about three out of ten patients with this diagnosis will eventually die from complications related to the disease.[6][11]

In patients receiving chemotherapy for advanced disease, the median overall survival from the start of treatment has been reported as 29 months (approximately two and a half years), though this varies considerably depending on individual circumstances. Some patients respond better to treatment than others, and factors such as the extent of disease, overall health, and response to therapy all influence survival outcomes.[9]

It’s important to understand that these statistics represent averages across many patients and may not predict what will happen in any individual case. Some people with dedifferentiated liposarcoma live much longer than average, especially if their tumor is caught early, can be completely removed surgically, and does not recur. Your healthcare team can provide more personalized information about prognosis based on your specific situation.[4]

Ongoing Clinical Trials on Dedifferentiated liposarcoma

  • Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Germany
  • Study of Pemigatinib and Retifanlimab for Patients with Advanced Dedifferentiated Liposarcoma

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark Norway Sweden
  • Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

    Recruiting

    1 1 1 1
    Cyprus Czechia Denmark France Germany Italy +4
  • Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

    Not yet recruiting

    1 1 1 1
    France Germany Italy Poland Spain
  • Study on Pembrolizumab and Olaparib for Patients with Resectable Soft Tissue Sarcoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on the Safety and Tolerance of BI 907828 in Patients with Advanced Dedifferentiated Liposarcoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Belgium Italy

References

https://sarcoma.org.uk/about-sarcoma/what-is-sarcoma/types-of-sarcoma/liposarcoma/dedifferentiated-liposarcoma/

https://pmc.ncbi.nlm.nih.gov/articles/PMC8348700/

https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/dedifferentiated-liposarcoma/

https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma/types/liposarcoma

https://pubmed.ncbi.nlm.nih.gov/11757866/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10253599/

https://sarcoma.org.uk/about-sarcoma/what-is-sarcoma/types-of-sarcoma/liposarcoma/dedifferentiated-liposarcoma/

https://www.nature.com/articles/s41598-017-12132-w

https://pmc.ncbi.nlm.nih.gov/articles/PMC8348700/

https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/dedifferentiated-liposarcoma/

https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma/types/liposarcoma

https://sarcoma.org.uk/about-sarcoma/what-is-sarcoma/types-of-sarcoma/liposarcoma/dedifferentiated-liposarcoma/

https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

https://www.mdanderson.org/cancerwise/understanding-liposarcoma–types–symptoms–prognosis—treatment.h00-159780390.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC6719806/

https://www.youtube.com/watch?v=ilcaR0lyms8

https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

How is dedifferentiated liposarcoma different from a regular lipoma?

Lipomas are benign noncancerous fatty tumors that feel soft and rubbery, typically measure no larger than 2 inches, and form just below the skin. Dedifferentiated liposarcoma is a malignant cancer that feels firmer, grows much larger, develops deeper in tissues, and has the potential to spread to other parts of the body. Your doctor can distinguish between them through physical examination and imaging tests, with a biopsy providing definitive confirmation.

What does MDM2 amplification mean and why is it important for diagnosis?

MDM2 is a gene located on chromosome region 12q13-15. In dedifferentiated liposarcoma, there are extra copies of this gene, a condition called amplification. This genetic abnormality is so characteristic of dedifferentiated liposarcoma that detecting it helps doctors confirm the diagnosis and distinguish this tumor from other types of sarcomas. The amplification disrupts normal cell processes and contributes to tumor growth.

Will I need multiple biopsies if my doctor suspects dedifferentiated liposarcoma?

Usually, one biopsy is sufficient to diagnose dedifferentiated liposarcoma. The biopsy sample is examined under a microscope and tested for genetic markers like MDM2 amplification. However, in some cases, if the initial biopsy sample is not adequate or doesn’t provide clear results, your doctor may need to perform another biopsy from a different area of the tumor to get enough tissue for accurate diagnosis.

How often will I need follow-up scans after treatment?

You will have regular follow-up appointments for several years after treatment, with the exact schedule determined by your sarcoma clinical nurse specialist. Follow-up typically includes physical examinations and may include MRI or ultrasound scans if needed to check for signs of recurrence. The frequency of these appointments and scans depends on factors such as your tumor’s location, whether it was completely removed, and your individual risk factors.

Can imaging tests alone diagnose dedifferentiated liposarcoma without a biopsy?

No, imaging tests like CT and MRI scans can show the presence and characteristics of a tumor, but they cannot definitively diagnose dedifferentiated liposarcoma on their own. A biopsy is essential for confirmation because it allows doctors to examine the tissue under a microscope and test for specific genetic markers like MDM2 amplification that distinguish dedifferentiated liposarcoma from other conditions.

🎯 Key takeaways

  • Dedifferentiated liposarcoma typically presents as a large, growing lump that feels firmer than benign lipomas and requires medical evaluation, especially in adults over 50.
  • Diagnosis requires a combination of physical examination, imaging tests (CT or MRI scans), and most importantly, a biopsy with genetic testing for MDM2 amplification.
  • The MDM2 gene amplification test serves as a definitive diagnostic marker that distinguishes dedifferentiated liposarcoma from other undifferentiated sarcomas.
  • About 107 cases of dedifferentiated liposarcoma are diagnosed annually in England, making it a rare form of cancer requiring specialist evaluation.
  • Clinical trial enrollment often requires additional diagnostic testing beyond standard diagnosis, including specific genetic marker confirmation and staging scans.
  • Recurrence occurs in 40 to 75 percent of dedifferentiated liposarcoma cases, making regular follow-up imaging surveillance critically important for early detection.
  • Tumors in the arms or legs tend to have better outcomes than those in the retroperitoneum because they can often be removed more completely with adequate margins.
  • Traditional tumor measurement methods may not fully capture treatment response in dedifferentiated liposarcoma, as vascular changes can occur without significant size reduction.